source
- T-Therapeutics secures $133 million Series B to advance bispecific cancer and autoimmune drugsT-Therapeutics, a UK-based biotech focused on T-cell engager technology, announced a $133 million Series B financing. The capital will be used to generate proof-of-concept data for its lead bispec…
- China clamps down on investigator-initiated biotech trials after patient deaths, halting rare-disease studiesChinese regulators have introduced new rules that sharply limit investigator‑initiated biotech trials after a series of patient deaths were reported this summer. The policy shift is intended to tig…